S. Res. 570 is a Senate resolution that designates November 2025 as "National Lung Cancer Awareness Month," names the first week of November 2025 as "National Women’s Lung Cancer Awareness Week," and designates the second Saturday in November 2025 as "National Lung Cancer Screening Day." The text collects epidemiological findings about incidence, mortality, risk factors, and screening gaps and expresses support for awareness, early detection, treatment, and research efforts, with special attention to minorities, veterans, and people who have never smoked.
The measure is ceremonial and does not create new funding or regulatory requirements. Its practical effect is to signal congressional attention to disparities in screening and diagnosis, to encourage public- and private-sector outreach around low-dose CT screening and biomarker testing, and to provide advocacy groups and agencies a federal reference point for awareness campaigns and coordination efforts.
At a Glance
What It Does
The resolution formally designates specific awareness observances in November 2025, recites detailed findings about lung cancer incidence, mortality, and screening shortfalls, and expressly supports efforts to increase education, screening, treatment, and research. It lists mitigation of risk factors, screening, treatment, and attention to minorities and never-smokers as prioritized areas.
Who It Affects
Directly implicated stakeholders include lung cancer patients and potential screening candidates (including veterans and never-smokers), public health agencies and community health organizations that run screening and outreach programs, health systems that deliver low-dose CT scans and follow-up care, and researchers and diagnostics companies involved in biomarker testing and targeted therapies.
Why It Matters
Although nonbinding, the resolution packages federal-level language and statistics that advocacy groups and agencies can use to justify outreach, educational campaigns, and prioritization of screening access. It highlights persistent gaps—low screening uptake, geographic and demographic disparities, and constrained access to diagnostics—that shape where resources and policy attention are likely to flow next.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
S. Res. 570 is a classic congressional resolution: it strings together a set of "whereas" findings about lung cancer and then adopts a short set of ceremonial designations and statements of support.
The preamble compiles a wide set of facts—projected diagnoses and deaths for 2025, the share of deaths attributable to cigarette smoking and secondhand smoke, lifetime risks by sex, racial disparities, veterans’ elevated risk, screening-eligibility estimates, and survival differences by stage. Those findings establish the factual basis for the designations and the calls for action that follow.
In substance the operative clauses do three things: they name November 2025 (and two specific observances within it) as times for national attention; they "support the purposes and ideals" of awareness month and promote efforts to increase education, screening, treatment, and research (explicitly including mitigation of risk factors and attention to minorities and never-smokers); and they encourage the public to observe the month with appropriate activities. The resolution does not appropriate money, change clinical guidelines, or alter insurance coverage rules; it is a statement of congressional intent and concern.The bill repeatedly emphasizes gaps that matter for implementation: an estimated large pool of people who meet screening criteria (tens of millions by prior estimates) alongside very low uptake (single-digit to low-double-digit percentages), geographic and transportation barriers to screening, uneven access to biomarker testing, and a stigma that can deter care-seeking.
By compiling these data in a congressional document, the resolution gives advocates and agencies a reference to support targeted outreach (for example toward veterans or women who never smoked) and to press for expanded screening capacity and diagnostic access.Practically, expect the resolution’s immediate utility to be reputational and programmatic rather than regulatory. Federal agencies, state health departments, the VA, and NGOs can cite the resolution to coordinate events, public-information campaigns, and pilot outreach programs; diagnostics firms and health systems may use the observance as a launch point for marketing or patient navigation initiatives.
What the resolution does not do—authorize funding, change reimbursement, or mandate coverage—means follow-through will depend on subsequent agency actions, appropriations, and private-sector commitments.
The Five Things You Need to Know
The resolution designates November 2025 as National Lung Cancer Awareness Month, the first week of November 2025 as National Women’s Lung Cancer Awareness Week, and the second Saturday of November 2025 as National Lung Cancer Screening Day.
It cites projected 2025 figures of about 226,650 new lung cancer diagnoses and 124,730 deaths and attributes roughly 109,100 of those deaths to cigarette smoking.
The bill notes that only about 16 percent of individuals at high risk for lung cancer undergo recommended lung cancer screening.
It highlights veterans specifically: veterans are described as 25 percent more likely than the general public to develop lung cancer, with 1,000,000 to 2,000,000 veterans eligible for screening but less than 3 percent actually screened.
The resolution records that an estimated 14,500,000 individuals were recommended for lung cancer screening as of 2021 and that 62 percent of adults are unfamiliar with lung cancer screening and low-dose CT scans.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Compiles epidemiology, risk factors, and access gaps
The preamble aggregates statistics on incidence, mortality, smoking-attributable deaths, lifetime risk by sex, racial and veteran disparities, screening-eligibility estimates, survival by stage, and familiarity with low-dose CT. That collection serves two functions: it documents congressional concern and creates a factual record advocates can cite when seeking resources or programmatic attention. Practically, these findings frame which populations (veterans, Black men, never-smokers, women) the resolution singles out for targeted awareness.
Creates three named observances in November 2025
This operative section formally designates November 2025 as National Lung Cancer Awareness Month, the first week as National Women’s Lung Cancer Awareness Week, and the second Saturday as National Lung Cancer Screening Day. These are ceremonial labels without independent legal effect, but they create calendar hooks for federal agencies, state health departments, advocacy groups, and private organizations to time campaigns, press releases, and outreach events.
Affirms support for screening, treatment, research, and attention to disparities
The resolution "supports the purposes and ideals" of awareness month and explicitly promotes efforts to mitigate risk factors, increase lung cancer screening, improve treatment, and focus on minorities and people who have never smoked. While not binding, this language signals congressional priorities that may influence agency messaging, grant solicitations, or public–private partnerships aimed at improving early detection and expanding access to biomarker testing and targeted therapies.
Encourages public observance
The resolution encourages the people of the United States to observe the month with appropriate awareness and educational activities. As a practical matter this clause invites civil-society actors and health systems to run patient education, screening drives, and anti-stigma campaigns, but it does not obligate federal funding or create enforcement mechanisms—implementation depends on downstream action by agencies and organizations.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Individuals at high risk for lung cancer: Increased federal recognition can drive outreach that improves awareness of low-dose CT screening and may increase early detection, which substantially improves 5-year survival for localized disease.
- Veterans: The resolution singles out veterans—who face higher incidence and low screening uptake—potentially focusing VA and veterans’ groups on targeted screening outreach and navigation services.
- Women who never smoked and other never-smoker patients: By calling out never-smoker cases and designating a women’s awareness week, the bill raises visibility for populations less associated with traditional smoking narratives and may reduce barriers to diagnosis.
- Public health and advocacy organizations: Ceremonial designation provides a federal imprimatur they can use to attract funding, recruit partners, and organize national campaigns around screening and stigma reduction.
- Diagnostics and biotech firms: Greater emphasis on screening and biomarker access creates opportunities for companies offering low-dose CT services, biomarker tests, and targeted therapies to participate in pilot programs, awareness campaigns, or partnerships.
Who Bears the Cost
- Federal agencies (e.g., CDC, VA): Although the resolution does not appropriate funds, agencies may face implicit pressure to mount outreach or coordinate programs—activities that require staff time and may need new funding if scaled.
- Health systems and imaging centers: Increased awareness and screening drives can produce surges in demand for low-dose CT and follow-up diagnostics, imposing capacity constraints and operational costs.
- Community organizations and state health departments: Local groups will likely bear the logistical and financial burden of running screening events and educational campaigns unless external funding is provided.
- Payers and insurers: If awareness efforts increase screening demand, insurers may face pressure to clarify coverage policies and potentially cover more screening-related services and downstream diagnostics and procedures.
- VA and veterans’ service organizations: Targeted outreach to veterans could require expanded outreach, navigation, and screening programs—again translating to resource needs even without new federal appropriations.
Key Issues
The Core Tension
The central dilemma is that the resolution pushes for more awareness and screening—actions that can save lives—while remaining nonbinding and unfunded; without parallel commitments to expand screening capacity, reduce geographic and socioeconomic barriers, and ensure equitable access to diagnostics and treatment, the effort risks widening disparities or overwhelming follow-up systems even as it increases visibility.
The resolution is declarative, not regulatory. Its primary limitation is that it calls for awareness, screening, and research without authorizing funding, changing clinical eligibility, or mandating coverage.
That creates a practical gap: recognition can increase demand for screening and diagnostics without guaranteeing resources to meet that demand or to address documented geographic and demographic access gaps.
Another tension concerns messaging. The bill highlights smoking as the cause of a majority of lung cancer deaths while also spotlighting never-smokers and groups with rising incidence.
Crafting public communications that acknowledge smoking’s role without stigmatizing patients—especially populations who never smoked or who already face barriers to care—will be essential and nontrivial. Finally, increasing screening uptake has known trade-offs: low-dose CT screening reduces mortality when targeted correctly, but it also produces false positives and downstream diagnostic burdens; resolving those trade-offs requires funded programs for navigation, follow-up, and equitable access to biomarker testing, none of which this resolution itself provides.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.